Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay
Author Information
Author(s): P. Hedberg, J. Valkama, E. Suvanto, S. Pikkujamsa, K. Ylitalo, E. Alasaarela, M. Puukka
Primary Institution: Oulu University Hospital
Hypothesis
The study aims to evaluate the performance of the Innotrac Aio! second-generation cardiac troponin I assay compared to other assays.
Conclusion
The second-generation Innotrac Aio! cTnI assay demonstrates very good analytical performance and is superior to the first-generation assay.
Supporting Evidence
- The assay was found to be linear within the tested range of 0.063-111.6 g/L.
- Within-assay CVs were 3.2%-10.9%, and between-assay precision ranged from 4.0% to 17.2%.
- The second-generation Innotrac Aio! cTnI assay was superior to the first-generation assay with regard to precision in the low concentration range.
- False-positive cTnI values occurred in the presence of very high rheumatoid factor values, over 3000 U/L.
- The 99th percentile of the apparently healthy reference group was 0.03 g/L.
Takeaway
This study tested a new blood test for heart damage that works faster and better than older tests.
Methodology
The study compared the Innotrac Aio! second-generation cTnI assay with other assays using serum samples from patients and evaluated sample stability and hemodialysis effects.
Potential Biases
False-positive results may occur in the presence of high rheumatoid factor levels.
Limitations
The study had a small sample size and may not be generalizable to all patient populations.
Participant Demographics
The study included patients with positive rheumatoid factor and no indication of myocardial infarction.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website